1. Understanding of cytokines and targeted therapy in macrophage activation syndrome
- Author
-
Shunli Tang, Siting Zheng, Jianjun Qiao, Dingxian Zhu, Sheng Li, Yuwei Ding, Chuanyin Sun, Hong Fang, and Yongxian Hu
- Subjects
Adult ,musculoskeletal diseases ,medicine.medical_treatment ,Arthritis ,Disease ,Systemic inflammation ,Targeted therapy ,Pathogenesis ,Rheumatology ,medicine ,Humans ,business.industry ,Macrophage Activation Syndrome ,fungi ,medicine.disease ,Arthritis, Juvenile ,Anesthesiology and Pain Medicine ,Macrophage activation syndrome ,Immunology ,Cyclosporine ,Cytokines ,lipids (amino acids, peptides, and proteins) ,medicine.symptom ,Complication ,Cytokine storm ,business ,Still's Disease, Adult-Onset ,hormones, hormone substitutes, and hormone antagonists - Abstract
Macrophage activation syndrome (MAS) is a potentially life-threatening complication of systemic autoinflammatory/autoimmune diseases, generally systemic juvenile idiopathic arthritis and adult-onset Still's disease. It is characterized by an excessive proliferation of macrophages and T lymphocytes. Recent research revealed that cytokine storm with elevated pro-inflammatory cytokines, including IFN-γ, IL-18, and IL-6, may be central to the pathogenesis of MAS. Though the mainstream of MAS treatment remains corticosteroids and cyclosporine, targeted therapies with anti-cytokine biologics are reported to be promising for controlling systemic inflammation in MAS.
- Published
- 2021